The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

@article{Visanji2008TheNF,
  title={The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease},
  author={Naomi P. Visanji and Rob M.A. de Bie and Tom H. Johnston and Andrew C McCreary and Jonathan M. Brotchie and Susan H. Fox},
  journal={Movement Disorders},
  year={2008},
  volume={23}
}
The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an… 

Nociceptin/Orphanin FQ Receptor Agonists Attenuate l-DOPA-Induced Dyskinesias

TLDR
N/OFQ receptor agonists may represent a novel strategy to counteract l-DOPA-induced dyskinesias and is possibly mediated by upregulated striatal N/OFq receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111

TLDR
The acute and long‐term antiparkinsonian effects of the novel compound 2‐[3‐[4‐(2‐chloro‐6‐fluoro‐phenyl)‐piperidin‐1‐ylmethyl]‐2‐(morpholine‐4‐carbonyl)‐indol‐ 1‐yl]‐acetamide (NiK‐21273) in comparison with the potent and selective NOP receptor antagonist SB‐612111 is reported.

Managing Parkinson's disease: moving ON with NOP

TLDR
The opioid‐like neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP receptor) contribute to Parkinson's disease (PD) and motor complications associated with levodopa therapy and might represent a novel target in the therapy of PD.

Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease

  • M. MartiS. Sarubbo M. Morari
  • Biology, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2010
TLDR
Data from this study provide the first clinical evidence linking N/OFQ to idiopathic Parkinson's disease in humans and strengthen the pathogenic role of N /OFQ in the modulation of parkinsonism across species and provide a rationale for developing N/ OFQ receptor antagonists as antiparkinsonian drugs.

Activation of Nociceptin/Orphanin FQ Peptide Receptors Disrupts Visual but Not Auditory Sensorimotor Gating in BALB/cByJ Mice: Comparison to Dopamine Receptor Agonists

TLDR
Results show that pharmacological stimulation of NOP or dopamine D2-like receptors is more potent in disrupting visual than acoustic PPI in mice, whereas D1-like receptor activation disrupts both, and suggest that dysfunction of N/OFQ transmission may be implicated in the pathogenesis of psychotic manifestations.

Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism

TLDR
It is demonstrated for the first time that N/OFQ is detrimental to the survival and growth of dopaminergic neurons and that its expression is altered in the midbrain of patients with Parkinson’s disease.

NOP Receptor Ligands and Parkinson's Disease.

TLDR
This chapter presents data showing that, in addition to motor symptoms, N/OFQ also plays a role in the parkinsonian neurodegeneration, and NOP receptor antagonists possess neuroprotective/neurorescue properties in in vitro and in vivo models of PD.

Nociceptinergic system as potential target in Parkinson's disease.

Nociceptinergic system has become an important target for drug development since the identification of the "orphan", opioid-like-1 receptor and the isolation of its endogenous agonist nociceptin.

References

SHOWING 1-8 OF 8 REFERENCES

The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway

By using a battery of behavioral tests, we showed that nociceptin/orphanin FQ receptor (NOP receptor) antagonists attenuated parkinsonian-like symptoms in 6-hydroxydopamine hemilesioned rats (Marti

Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

TLDR
The results obtained in this study suggest that histamine H3 receptors may be involved in the neural mechanisms underlying L‐dopa–induced dyskinesia in Parkinson's disease.

Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease

TLDR
Evidence suggesting that endogenous N/OFQ may contribute to Parkinson's disease is presented and it is proposed that NOP receptor antagonists may represent a novel approach for combined (symptomatic and neuroprotective) therapy of Parkinson’s disease.

Blockade of Nociceptin/Orphanin FQ Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior

TLDR
It is concluded that NOP receptors in the substantia nigra pars reticulata, activated by endogenous N/OFQ, drive a physiologically inhibitory control on motor behavior, possibly via modulation of the nigrostriatal dopaminergic pathway.

Nondopaminergic mechanisms in levodopa‐induced dyskinesia

  • J. Brotchie
  • Biology, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2005
TLDR
It is speculated that the external globus pallidus and subthalamic nucleus may play distinct roles in different forms of dyskinesia, e.g., chorea/dystonia; peak/diphasic/off.

Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

TLDR
By assessing the actions of drugs known to enhance or attenuate psychosis in PD patients, it is found that the pharmacology of these behaviors recapitulates, in several respects, the Pharmacology of psychosis inPD.

Novel pharmacological targets for the treatment of Parkinson's disease

TLDR
This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.

Levodopa‐induced dyskinesias

TLDR
This review focuses on three issues related to Levodopa‐induced dyskinesia: clinical features, classification and rating, pathophysiology and pathogenesis, and management.